Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
70
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (1406 trials with phase data)• Click on a phase to view related trials
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 188
- Registration Number
- NCT07170917
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
- Conditions
- Microscopic Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT07156175
A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 212
- Registration Number
- NCT07146750
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT07135973
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
- Conditions
- Meningococcal InfectionHealthy Volunteers
- Interventions
- Biological: MenAC conjugate vaccine
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1504
- Registration Number
- NCT07135986
- Prev
- 1
- 2
- 3
- 4
- 5
- 297
- Next
News
Enveda Biosciences Raises $150M Series D to Advance AI-Driven Drug Discovery Platform
Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.
Sanofi Shares Plummet 10% as Amlitelimab Phase III Data Falls Short of Dupixent Expectations
Sanofi's experimental atopic dermatitis drug amlitelimab met all primary endpoints in Phase III trials but showed weaker efficacy compared to the company's blockbuster drug Dupixent.
ArcaScience Secures $7M to Accelerate AI-Driven Drug Safety Evaluation Platform
ArcaScience raised $7 million in seed funding to expand its AI platform that transforms drug benefit-risk assessments from months-long processes to seconds-long computations.
Sanofi's Wayrilz Becomes First BTK Inhibitor Approved for Immune Thrombocytopenia Treatment
The FDA approved Wayrilz (rilzabrutinib) as the first BTK inhibitor for adults with persistent or chronic immune thrombocytopenia who have insufficient response to prior treatments.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
Merck KGaA Partners with Skyhawk Therapeutics in $2 Billion RNA Splicing Collaboration for Neurological Disorders
Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.
Major Pharma M&A Surge and Landmark Antitrust Rulings Shape 2025 Life Sciences Landscape
The first half of 2025 witnessed unprecedented M&A activity with major deals including Merck's $3.9 billion SpringWorks acquisition, Sanofi's $9.5 billion Blueprint Medicines purchase, and Johnson & Johnson's $14.6 billion Intra-Cellular Therapies acquisition.
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer Following Positive Phase 3 Results
PolyPid Ltd. has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025, following positive Phase 3 SHIELD II trial results for their lead product candidate D-PLEX100.
RIPK1 Inhibitor Pipeline Shows Promise Despite Sanofi Setback in Multiple Sclerosis
Over 10 companies are developing 12+ RIPK1 inhibitor therapies targeting inflammatory and neurodegenerative diseases, with key players including Sanofi, Rigel Pharmaceuticals, and GenFleet Therapeutics advancing promising candidates.
Allan Camaisa Joins Res Nova Biologics Advisory Board to Advance Breast Cancer Immunotherapy
Former Calidi Biotherapeutics Chairman and CEO Allan Camaisa has joined Res Nova Biologics' Advisory Board to accelerate development of breast cancer immunotherapies.